The latest: Products from Hutchmed (China) Ltd. (HCM.US; 0013.HK), Zai Lab Ltd. (ZLAB.US; 9688.HK) and Ascentage Pharma Group (6855.HK) were among 111 new drugs selected for new inclusion in the 2022 edition of China’s National Reimbursement Drug List under the nation’s national health plan.

Looking up: The inclusion of their products on the list will help the companies gain market share, boosting their future sales.

Take Note: Products are required to offer major price concessions in exchange for inclusion on the list. Reflecting that, the 111 drugs added to the latest list were forced to lower their prices by 60.1% on average. Thus, inclusion on the list may improve unit sales, but can severely erode a company’s margins.

Digging Deeper: Hutchmed’s selected product on the list is Orpathys, an oral MET tyrosine kinase inhibitor for the treatment of adults with non-small cell lung cancer, jointly developed with AstraZeneca (AZN.LON). Zai Lab got the intravenous infusion dosage forms of its Qinlock and Nuzyra drugs included on the list, the former used to treat advanced gastrointestinal stromal tumors, and the latter for bacterial pneumonia and acute bacterial skin and skin structure infections. Ascentage Pharma’s third-generation BCR-ABL inhibitor Olverembatinib, a drug for treating chronic myeloid leukemia, was included in the list.

Market Reaction: Zai Lab’s Hong Kong shares dropped 1.7% to HK$34.60 by the midday break on Thursday. Hutchmed’s shares were unchanged at HK$27.50 over that time, while Ascentage Pharma rose 2.7% to HK$24.70.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Qudian abandons last mile delivery

Qudian: A slow-motion privatization?

The company said it is contemplating winding down its last-mile delivery service after stiff competition caused its revenue to plunge in the first quarter Key Takeaways: Qudian’s revenue fell by…
Yeahka secures bridgehead in U.S. payments market

Yeahka secures bridgehead in U.S. payments market

The Chinese fintech has cleared one of many regulatory hurdles to enter the U.S. digital payments business after gaining a state-level operating license Key Takeaways: After getting U.S. federal clearance,…
Sante makes infant nutritional products

Sainte Nutritional nurtures Hong Kong IPO

The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutritional has filed…